Urea glucokinase activators
View Patent ↗This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.
1. A compound selected from the group consisting of:
3-{2-[3-Cyclopentylmethyl-3-(4-fluoro-3-methoxy-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
3-{2-[3-Cyclopentylmethyl-3-(2,4-difluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
3-{2-[3-Cyclopentylmethyl-3-(2,3-difluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
3-{2-[3-Cyclopentylmethyl-3-(2,3-difluoro-4-methoxy-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-2,5-difluoro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-tert-Butyl-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(4-methylsulfanyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-2-methyl-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-2-fluoro-5-methyl-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(2-fluoro-4-methanesulfonyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(3,4-dichloro-2-fluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(3-Acetylamino-2,4-difluoro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
(2-{3-Cyclopentylmethyl-3-[3-(3-methyl-[1,2,4]oxadiazol-5-yl)-phenyl]-ureido}-thiazol-5-ylsulfanyl)-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(3-fluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(2-Fluoro-4-bromo-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(2-methoxy-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(2-fluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
[2-(3-Cyclopentylmethyl-3-p-tolyl-ureido)-thiazol-5-ylsulfanyl]-2,2-dimethyl-propionic acid;
{2-[3-(4-Chloro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(2-trifluoromethyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(4-fluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(2-fluoro-4-methoxy-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(3-methoxy-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
[2-(3-Cyclopentylmethyl-3-tolyl-ureido)-thiazol-5-ylsulfanyl]-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(2,4-dichloro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(2-Chloro-4-fluoro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Chloro-2-fluoro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(2-Chloro-4-methyl-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(2-fluoro-4-methyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(4-fluoro-2-trifluoromethyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(4-isopropyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-3-methoxy-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
(2-{3-Cyclopentylmethyl-3-[2-fluoro-4-(2-methoxy-ethoxy)-phenyl]-ureido}-thiazol-5-ylsulfanyl)-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-3-trifluoromethoxy-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-3-fluoro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-3-chloro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Chloro-2-trifluoromethyl-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-3-methyl-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(3-oxazol-2-yl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(4-phenylsulfanyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-2,6-difluoro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(4-methyl-2-trifluoromethyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
(2-{3-Cyclopentylmethyl-3-[4-(2-methoxy-ethoxy)-phenyl]-ureido}-thiazol-5-ylsulfanyl)-2,2-dimethyl-propionic acid;
(2-{3-Cyclopentylmethyl-3-[4-(morpholine-4-sulfonyl)-phenyl]-ureido}-thiazol-5-ylsulfanyl)-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(4-ethoxy-2-fluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-Cyclopentylmethyl-3-(3-methanesulfonyl-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(3-Butylsulfamoyl-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(4-Bromo-3-chloro-2-fluoro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
{2-[3-(2-Chloro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid; and
{2-[3-(3-Chloro-phenyl)-3-cyclopentylmethyl-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid;
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
3. A method for the treatment or alleviation of type 2 diabetes comprising administering to a subject in need thereof a compound according to claim 1 .
4. A process for preparing a pharmaceutical composition according to claim 2 comprising formulating the compound with pharmaceutically acceptable substances and/or excipients.
5. A method for the treatment or alleviation of type 2 diabetes comprising administering to a subject in need thereof a pharmaceutical composition according to claim 2 .
6. The compound of claim 1 , wherein the compound is 3-{2-[3-Cyclopentylmethyl-3-(2,4-difluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid or pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein the compound is 3-{2-[3-Cyclopentylmethyl-3-(2,3-difluoro-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid or pharmaceutically acceptable salt thereof.
8. A compound of claim 1 , wherein the compound is 3-{2-[3-Cyclopentylmethyl-3-(2,3-difluoro-4-methoxy-phenyl)-ureido]-thiazol-5-ylsulfanyl}-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising a compound according to claim 7 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising a compound according to claim 8 and a pharmaceutically acceptable carrier.